



## Expanded Access Use Policy

---

Paratek Pharmaceuticals (Paratek) is a biopharmaceutical company committed to developing novel life-saving drugs for serious or life-threatening diseases.

“Expanded access” refers to use of an investigational drug outside of a clinical trial, where the use of the drug is for treatment, rather than data gathering in support of a marketing application.

Paratek's goal is to gain information about the safety and efficacy of an investigational drug to submit an application to Health Authorities in support of approval to market the investigational drug. For this reason, Paratek believes that direct enrollment in a clinical trial is the preferred route of access to a drug, for which we are continuing to develop data on safety, efficacy and tolerability. We believe expanded access outside of a clinical trial may interfere with the conduct of ongoing trial(s) and may disrupt the progress of our development programs, which could potentially delay access to other patients in need.

For this reason, Paratek is not making its drugs available on an expanded access basis at this time. We will reevaluate this policy in the future as additional information becomes available.

If you have any questions about this policy or would like information about how to participate in our clinical studies, please contact us at: [medinfo@paratekpharma.com](mailto:medinfo@paratekpharma.com).

As authorized by the 21<sup>st</sup> Century Cures Act, Paratek may revise this expanded access policy at any time. Additionally, the posting of this policy by Paratek shall not serve as a guarantee of access to any specific investigational drug by any individual patient.